Richard A. Paulson M.B.A. Net Worth

The estimated Net Worth of Richard A. Paulson is at least $1.53 Million dollars as of 4 September 2024. Mr Paulson owns over 3,667 units of Karyopharm Therapeutics Inc stock worth over $843,018 and over the last 5 years he sold KPTI stock worth over $639,595. In addition, he makes $52,377 as Pres und CEO & Director at Karyopharm Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr A KPTI stock SEC Form 4 insiders trading

Mr has made over 31 trades of the Karyopharm Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 3,667 units of KPTI stock worth $2,640 on 4 September 2024.

The largest trade he's ever made was selling 99,844 units of Karyopharm Therapeutics Inc stock on 29 February 2024 worth over $117,816. On average, Mr trades about 6,830 units every 22 days since 2020. As of 4 September 2024 he still owns at least 1,139,214 units of Karyopharm Therapeutics Inc stock.

You can see the complete history of Mr Paulson stock trades at the bottom of the page.

Mr. Richard A. Paulson M.B.A. biography

Richard A. Paulson M.B.A. is the Pres, CEO & Director at Karyopharm Therapeutics Inc.

What is the salary of Mr A?

As the Pres und CEO & Director of Karyopharm Therapeutics Inc, the total compensation of Mr A at Karyopharm Therapeutics Inc is $52,377. There are 16 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.

How old is Mr A?

Mr A is 54, he's been the Pres und CEO & Director of Karyopharm Therapeutics Inc since . There are 11 older and 12 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.

What's Mr A's mailing address?

Richard's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.

Insiders trading at Karyopharm Therapeutics Inc

Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic... und Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.

What does Karyopharm Therapeutics Inc do?

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Complete history of Mr Paulson stock trades at Bluebird bio Inc und Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc executives and stock owners

Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ran Frenkel,
  Chief Development Operations Officer
• Michael Kauffman,
  Co-Founder, Chief Executive Officer and Director
• Sharon Shacham,
  President, Chief Scientific Officer
• Christopher Primiano,
  Executive Vice President, Chief Business Officer, General Counsel and Secretary
• Dr. Michael G. Kauffman M.D., Ph.D.,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Michael G. Kauffman,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Sharon Shacham M.B.A., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Sharon Shacham,
  Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board
• Michael P. Mason CPA, M.B.A.,
  Sr. VP, CFO & Treasurer
• Mansoor Mirza,
  Director and Clinical Advisor
• Barry Greene,
  Lead Independent Director
• Deepa Pakianathan,
  Independent Director
• Garen Bohlin,
  Independent Director
• Dr. Mansoor Raza Mirza M.D.,
  Clinical Consultant, Member of Scientific Advisory Board & Independent Director
• Mikael Dolsten,
  Independent Director
• Dr. Mansoor Raza Mirza,
  Clinical Consultant, Member of Scientific Advisory Board & Director
• Richard A. Paulson M.B.A.,
  Pres, CEO & Director
• Richard Paulson,
  Independent Director
• Christy Oliger,
  Director
• Perry Monaco,
  Senior Vice President of Sales
• Jatin Shah,
  Executive Vice President, Chief Medical Officer
• Tanya Lewis,
  Executive Vice President, Chief Regulatory Officer and Quality Officer
• Michael Mason,
  Chief Financial Officer, Senior Vice President, Treasurer
• James Accumanno J.D.,
  Chief Compliance Officer
• Elhan Webb C.F.A.,
  Sr. VP of Investor Relations
• Lisa Meletta J.D.,
  VP of Legal & Chief Compliance Officer
• Michael J. Mano J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Pierre S. Sayad M.S., Ph.D.,
  VP of Global Medical & Scientific Affairs
• Cameron Peters,
  VP of Fin., Assistant Treasurer & Principal Accounting Officer
• Ran Frenkel R.Ph., RPh,
  Exec. VP & Chief Devel. Officer
• Zhen Su,
  
• Carsten Thiel,
  Director
• Kenneth E Weg,
  Director
• J. Scott Garland,
  Director
• Justin A Renz,
  EVP, CFO & Treasurer
• Michael Falvey,
  EVP, CFO & Treasurer
• Peter Honig,
  Director
• Anand Varadan,
  EVP, Chief Commercial Officer
• Cameron Peters,
  VP of Finance
• Marcin Hadjimichael Andreas...,
  
• Paul Brannelly,
  SVP, FIN & ADMIN, SEC & TRES
• Ltd Czernik Marcin Hadjimic...,
  
• Ltd Czernik Marcin Hadjimic...,
  
• John Demaree,
  Chief Commercial Officer
• Deepika Pakianathan,
  
• Chen Schor,
  
• Stephen Mitchener,
  SVP, Chief Business Officer
• Michael Mano,
  SVP, General Counsel&Secretary
• Sohanya Roshan Cheng,
  EVP & Chief Commercial Officer
• Stuart Poulton,
  EVP, Chief Development Officer
• Reshma Rangwala,
  EVP & Chief Medical Officer